Maxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio Inc (INMB) yesterday and set a price target of $13. The company’s shares opened today at $9.14.
McCarthy wrote:
“INmune Bio reported positive preliminary data from its ongoing Phase 1 study of INB03 (selective anti-TNF) in patients with advanced solid tumors. Also important to note is that this is the first set of clinical data to emerge for INmune, and in our view marks a milestone as management executes on driving the immunology-focused pipeline.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -24.9% and a 19.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Achieve Life Sciences Inc, and Adial Pharmaceuticals Inc.
Currently, the analyst consensus on Inmune Bio Inc is a Moderate Buy with an average price target of $13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.50 and a one-year low of $7. Currently, Inmune Bio Inc has an average volume of 14.87K.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INMB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
